Drug intelligence / Profile preview

KR230109

Development stage: Phase 2
Lead developer: Jiangxi Kerui Pharmaceutical
Modality: Small Molecules

Overview

KR230109 is a small molecule chemical drug developed by Jiangxi Kerui Pharmaceutical. It is being investigated for the treatment of acne vulgaris, a common skin and musculoskeletal disease. As of March 2025, its highest global R&D status is Phase 1 (IND approval) in China. The precise mechanism of action and molecular target have not been disclosed in public sources[1][3][4]. No clinical trial results or additional indications are currently available.

Other names: KR-230109KR230109KR 230109

Beyond the preview

Go deeper on KR230109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KR230109.

Explore the full profile